AstraZeneca PLC (LON: AZN) has announced plans to harmonize its listing structure across the London Stock Exchange (LSE), Nasdaq Stockholm (STO), and the New York Stock Exchange (NYSE).
The move, revealed in a release on Monday, aims to broaden the company's access to global capital markets and enhance its appeal to a wider range of investors.
The core of the harmonization involves a direct listing of AstraZeneca ordinary shares on the NYSE. This will replace the existing American Depositary Receipts (ADRs) listed on Nasdaq.
The company emphasised that its headquarters, tax residency, and listing on the LSE and STO will remain unchanged, ensuring continued inclusion in the FTSE 100 and OMX Stockholm 30 indices.
Michel Demaré, Chair of AstraZeneca, stated: “Today we set out our proposed harmonised listing structure which will support our long-term strategy for sustainable growth, while remaining headquartered in the UK and listed in London, Stockholm and New York. Enabling a global listing structure will allow us to reach a broader mix of global investors and will make it even more attractive for all our shareholders to have the opportunity to participate in AstraZeneca's exciting future.”
Searching for the Perfect Broker?
Discover our top-recommended brokers for trading or investing in financial markets. Dive in and test their capabilities with complimentary demo accounts today!
- Admiral Markets More than 4500 stocks & over 200 ETFs available to invest in – Read our Review
- Vantage High levels of account and deposit protection – Read our Review
- eToro Wide range of instruments available to trade – Read our Review
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY
